Regulation of Male Fertility by the Renin-Angiotensin System by Gianzo Citores, Marta & Subirán Ciudad, Nerea
 International Journal of 
Molecular Sciences
Review
Regulation of Male Fertility by the Renin-
Angiotensin System
Marta Gianzo 1 and Nerea Subirán 1,2,3,*
1 Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU),
48940 Leioa, Spain; marta.gianzo@ehu.eus
2 Innovation in Assisted Reproduction Group, Biocruces-Bizkaia Health Research Institute,
48903 Barakaldo, Spain
3 Research and Development Department, MEPRO Medical Reproductive Solutions,
20009 San Sebastian, Spain
* Correspondence: nerea.subiran@ehu.eus
Received: 30 September 2020; Accepted: 19 October 2020; Published: 26 October 2020


Abstract: The renin-angiotensin system (RAS) is a peptidic system known mainly for its roles in the
maintenance of blood pressure and electrolyte and fluid homeostasis. However, several tissues and
cells have been described to possess an intrinsic RAS that acts locally through different paracrine
and autocrine mechanisms. In the male reproductive system, several components of this system
have been observed in various organs and tissues, such as the testes, spermatozoa and seminal fluid.
Some functions attributed to this local RAS are maintenance of seminal plasma electrolytes, regulation
of steroidogenesis and spermatogenesis, and sperm functions. However, their specific actions in
these locations are not fully understood. Therefore, a deep knowledge of the functions of the RAS at
both the testicular and seminal levels could clarify its roles in male infertility and sperm physiology,
and the different RAS elements could be used to design tools enabling the diagnosis and/or treatment
of male infertility.
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1. Introduction
According to the World Health Organization (WHO), infertility is defined as the inability to
achieve pregnancy after a year of normal sexual relationships without the use of any contraceptive
method. Infertility is one of the most prevalent chronic health disorders involving young adults,
caused by advanced parental age and our lifestyle among other factors [1]. Suffering one in six couples
of reproductive age, this disease has a current estimated prevalence of 14% worldwide and it affects
both men and women; in fact, 50% of cases are due to the female partner, and the other 50% are due to
the male partner [1,2].
Male infertility is mainly caused by anatomical defects, genetic diseases and injuries, as well as
testicular sperm and hormonal dysfunction [3–5]. The production of fully functional spermatozoa
capable of movement and fertilization is under strict endocrine, paracrine and autocrine regulation.
Deregulation of this hormonal control or alterations in the different key cellular communication
systems can cause male infertility [4,5]. However, the precise causes of male infertility remain
unexplained in approximately 30% of cases, as many reproductive defects cannot be detected with
current diagnostic methods [2].
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RAS is a communication system that is reported to play a key role in the regulation of reproductive
function in both males and females [6,7]. In the female reproductive system, the RAS is involved
in many physiological and physiopathological processes, such as oocyte maturation and quality
control, endometrial lining production and/or hormone production, polycystic ovary syndrome,
ovarian hyperstimulation syndrome and ovarian or endometrial cancer [7]. In this review, we focus on
providing an update of recent important findings of the role of RAS in male reproductive function,
which is capable of the regulation of male fertility at multiple levels [6,8,9]. In fact, multiple RAS family
members are expressed on different male reproductive tissues, such as the testes and semen, where they
regulate male fertility, acting synergistically with and/or independently of systemic RAS [6].
2. The Renin-Angiotensin System (RAS)
The RAS is a peptidic system with endocrine characteristics known mainly for its importance
in the maintenance of blood pressure (BP) and electrolyte and fluid homeostasis [6]. This system is
canonically considered to be a circulating hormonal system that exerts its functions through angiotensin
II (Ang II) and aldosterone. This pathway is activated when renin is released by the kidneys into
the bloodstream in response to decreased BP, sympathetic nervous system activation and/or sodium
depletion [6]. This renin acts on angiotensinogen (AGT) of hepatic origin, forming angiotensin I (Ang I).
The inactive Ang I peptide is hydrolysed by the angiotensin-converting enzyme (ACE), giving rise
to the peptide with the highest activity in this system, Ang II, which ultimately exerts its action by
interacting with Ang II type 1 and 2 receptors (AT1R and AT2R) [6,10]. Ang II signalling produces
several responses, such as vasoconstriction of the peripheral circulation, increased sympathetic system
activity, release of vasopressin, increased cardiac chronotropism, and release of aldosterone from
the adrenal cortex, which can restore blood volume and pressure. In turn, Ang II itself inhibits the
synthesis and release of renin, regulating the activation of the RAS [6].
This traditional concept of the RAS has been revised due to the discovery of new RAS family
members, which has provided evidence of the existence of new non-canonical pathways of this system
(Figure 1). Principally, the field was redefined by the discovery of ACE2, an ACE homologue that
cleaves Ang II to generate angiotensin 1–7 (Ang 1–7), which activates the Mas receptor (MasR). Later,
the list of pathway members was extended when another fragment of Ang II, Ang 3–8 (also called
Ang IV), was observed; Ang 3–8 acts on its own receptor, insulin-regulated aminopeptidase (IRAP,
also called AT4R) [11]. Finally, the (pro)renin receptor (PRR), on which prorenin and renin act directly,
was described [12]. The appearance of all these new RAS components has implied that this response
system involves complex interplay among various angiotensin receptors and their signalling pathways,
as well as receptor-like activity of RAS enzymes that can promote Ang II-independent intracellular
enzymatic pathways [11].
In recent years, attention has also been paid to evidence of a widespread local tissue RAS. This new
concept emerged after discovery of the existence of different RAS family members in several tissues
that are able to regulate several specific functions, working synergistically with or independently of the
systemic RAS [6,11]. These local RASs are mainly characterized by (1) the presence of different RAS
components, such as AGT and converting enzymes; (2) local synthesis of Ang II and other angiotensins;
and (3) the presence of the specific receptors. However, the local production of bioactive peptides is not
necessarily dependent on local expression of all components of the local tissue RAS, since components
from the circulation, such as renin, can also be taken up [7]. In fact, it has been observed that local RASs
are present in a wide range of systems, organs, and tissues, such as the kidneys, brain, cardiovascular
system, pituitary gland, adipose tissue, skin, adrenal gland, and female and male reproductive systems;
these RASs play important roles in many physiological processes, such as, cell growth, extracellular
matrix formation, vascular proliferation, endothelial function and apoptosis [11,13]. Furthermore,
local RASs can also interact with other signalling pathways, including those involving tachykinins,
enkephalins, nitric oxide (NO), prostaglandins or cellular phosphatases [6,13].
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Figure 1. Current view of the RAS. Canonical or systemic pathway is shown in blue, while the
no-canonical axes are shown in red. Peptide abbreviations: AGT, angiotensinogen; Ang I, angiotensin I;
A g II, ngiotensin II; A g III, angiotensin III; Ang IV, angiotensin (3–8) or IV; Ang (1–9), angiotensin
(1–9); Ang (1–7), a giote sin (1–7). Receptor abbreviatio s: AT1R, Ang II receptor type 1; AT2R, A g II
type 2 receptor; AT4R/IRAP, Ang IV receptor; MasR, Ang receptor (1–7) or Mas receptor; PRR, (pro)renin
rece tor. Enzyme abbreviations: CE, angiotensin-converting enzyme; ACE2, angiotensin-converting
enzyme 2; NEP, neutral endopept dase; APA, amin peptidase A; APN, aminopeptid se N; APB,
aminopeptidase B.
Along with the local synthesis and uptake of RAS elements by tissues, there is increasing evidence
that both synthesis and uptake also occur at he cellular level, which suggests a new mechanism of
action for a physiological sy tem called the intracellul r RAS [14]. This new intracellular system is
characterized by the presence of different RAS components inside the cell and by the synthesis of Ang
II at an intracellular ite. The concept of this system is based on (1) observation of the exist nce of
diverse isoforms of AGT nd re in (as a resul of gly sylation and alternative plici g, resp ctively)
and different forms of ACE (intracellular and sec ted), (2) th existence of alternative enzymes for
the synthesis of Ang II (such as cathepsin and chymase), and (3) intracellular detection of these
components under pa ticular cellular co ditions. In addition, these components must be able to
mediate bi logical effects from an intracellular ocation to be functionally relevant [15]. In fact, change
in cell structure and gene transcription have been repo ted to induce he m ilization of intracellular
calcium deposits and st mulate he growth of different cell types have been reported [13,15]. In spite of
that, the functional rol s of the intracellular RAS in physio ogy and pathophysiology have not yet been
fully elucidated.
Axes that Compose the RAS
Nowadays, RAS has been described as a complex system composed by the canonical axis as well as
the non-canonical axes (Figure 1), whose components are widely expressed in all cell types and organs
in humans. Therefore, RAS plays important roles in numerous physiological events, such as renal,
neuronal, cardiac, pancreatic, vascular, adrenal, pituitary, cognitive, ageing-related, inflammatory and
reproductive processes [16]. Notably, one of the most relevant functions of the RAS is its participation
in various processes related to male fertility [7,8,17,18].
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Renin/ACE/Ang II/AT1R/AT2R axis is a well-known pathway as it is considered the canonical or
systematic pathway, which is mainly formed by AGT; renin; ACE; Ang I and Ang II and their receptors,
AT1R and AT2R. Angiotensin III (angiotensin (2–8) or Ang III) is produced from Ang II through the
action of the enzyme aminopeptidase A (APA) and exerts its actions through AT1R and AT2R [6,10].
Traditionally, the main functions of this axis were considered to be the maintenance of BP and electrolyte
and fluid homeostasis. Other functions have since been attributed to the axis at the local and intracellular
levels, which differ depending on the receptor that triggers the signal [6,15]. AT1R is definitively
known to operate through various signalling mechanisms, such as by increasing the intracellular
levels of Ca2+ (by increasing the influx of extracellular Ca2+ and the mobilization of intracellular Ca2+);
activating various kinase pathways, including the mitogen-activated protein (MAP) kinase pathway;
and activating the epidermal growth factor receptor (EGFR) in the plasma membrane. In contrast,
the effects of AT2R stimulation are mediated mainly by phosphatases [19]. Therefore, the effects of
AT2R- and AT1R-mediated signalling have been considered to be antagonistic [6,10,19]. AT1R has thus
been associated with physiological responses such as vasoconstriction, the inflammatory response,
cell proliferation or oxidative stress, while AT2R has been associated with processes such as vasodilation;
apoptosis; and anti-inflammation, anti-cell proliferation and anti-oxidative stress processes [19].
The proteolysis cascade of ACE2/Ang(1–7)/MasR non-canonical axis starts with ACE2. This enzyme
cleaves Ang II to directly generate Ang (1–7), which exerts its action by binding to MasR. Additionally,
Ang I can be cleaved by many other peptidases, especially neutral endopeptidase (NEP), which can
generate Ang (1–7). Finally, this heptapeptide can also be generated via the hydrolysis of Ang I by
ACE2 to form angiotensin (1–9) (Ang (1–9)), which is subsequently cleaved by NEP or ACE. However,
it is important to highlight that this pathway seems to be catalytically less efficient than the ones
mentioned above [20]. Different studies have observed antagonistic effects between the proteins Ang II
and Ang (1–7) as well as among the receptors on which they act, the G-protein coupled receptors
(GPCRs) MasR and AT1R [7]. Indeed, the beneficial effects of this axis encompass various biological
processes, such as vasodilation and the stimulation of bradykinin and NO release [20].
The Ang IV/AT4R-IRAP axis is another non-canonical axis. In this signalling pathway, Ang III is
transformed into angiotensin (3–8), also called angiotensin IV (Ang IV), by the action of aminopeptidase
N (APN) and aminopeptidase B (APB). Ang IV ultimately acts through binding to AT4R/IRAP [21].
This axis plays key roles in the regulation of cognitive functions such as learning and memory,
renal metabolism, cardiovascular damage, modulation of glucose uptake into cells, and regulation of
the growth of several cell types [13].
Finally, the (pro)renin/PRR axis has been described after discovery of the existence of the renin
receptor (PRR) [12], which acts independently of the classical axis after activation by renin itself
and its precursor, (pro)renin [12,22] and it has been linked to cardiovascular, renal and degenerative
diseases [22].
3. The RAS and Male Fertility
The establishment of male fertility comprises a series of intricate and highly structured steps that
depend on complex orchestration of communication systems, especially the RAS. In fact, numerous
components of this system have been described in many organs and tissues of the male reproductive
tract, including the epididymis [23,24], vas deferens [25], prostate [26], seminal fluid [27–29], testes [9,30],
and spermatozoa [8,31–33]. In addition, accumulating data from in vitro, animal and clinical studies have
indicated that this peptide system is involved in the correct functioning of the human male reproductive
system and is frequently altered or deregulated in pathological conditions [8,18,22,29,31–33].
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3.1. Regulation of Testicular Function by Local RAS
The main functions of the testes are the formation of spermatozoa, or spermatogenesis, and the
production of testosterone, or steroidogenesis. Considering the importance and complexity of these
processes, it is easy to understand the strict endocrine, paracrine and autocrine regulation to which
they must be subject and how their deregulation can contribute to male infertility [4,5]. The first point
of hormonal regulation of testicular function is the hypothalamic-pituitary-testicular axis [5]. Several
members of the RAS are present in the testes, such as renin and Ang II, and are regulated by sex
hormones as well as by gonadotropins [30,34] (Figure 2). Likewise, various paracrine and autocrine
mechanisms modulate testicular function at the local level by acting on different types of cells present
in this tissue, such as Sertoli, Leydig and/or spermatogenic cells [4]. At this point, the local RAS
becomes involved; this RAS is isolated from the plasma RAS by a testicular blood barrier that protects
male fertility from substances such as AT1R blockers and ACE inhibitors [22]. Within this local system,
numerous researchers have found evidence of the synthesis and presence of components of different
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testosterone  are  due  to  direct  action  on  the  PRR  or  signalling  through  the  canonical  pathway. 
Figure 2. Endocrine regulation of the testicular RAS. At the testicular level, after gonadotropin
stimulation, the levels of Ang II and renin increase, while the expression of the genes encoding both
Ang II receptors as well as the levels of the receptors decrease. On the other hand, after hypophysectomy,
the levels of renin decrease, but the mRNA expression of AT1R and AT2R increases. At the cellular
level, in Leydig cells, exogenous administration of gonadotropins increases the levels of Ang I and II
and renin, whereas oestrogen treatment or hypophysectomy decreases renin levels.
3.1.1. The Reni /ACE/Ang II/AT1R/AT2R Axis
All members of this axis have been found in the testes of various mammals, including humans
(Table 1). The initial studies carried out in this regard showed that the major elements of this axis,
AGT [34] and renin [35–37], are present in Leydig cells. At first it was thought that these proteins
originated in the systemic RAS, since the testicular levels of AGT and renin and subsequently ACE,
Ang II and its receptors increase at the beginning of puberty with the appearance of LH and FSH
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in the bloodstream [8,38,39]. Later, it was observed that their transcripts are synthesized in Leydig
cells [6,34,40], indicating their local production and the linked regulation between the systemic
and local RAS [22]. In addition, it has been found that increases in renin levels cause increases in
testosterone synthesis [38]; however, further studies are necessary to elucidate whether such increases
in testosterone are due to direct action on the PRR or signalling through the canonical pathway.
Likewise, Ang I has also been found in the testes, mainly in Leydig cells [41], serving as a substrate
for ACE. In fact, the testes also contain much higher concentrations of ACE (also known as ACE1)
than other organs [6,42]. Interestingly, in the testes, two isoforms of this enzyme, somatic ACE
(sACE) and testicular or germinal ACE (tACE or gACE), have been observed. Even though both
are transcribed from the same gene, they differ structurally by the presence/absence of a 66-amino
acid sequence [43] and consequently present different molecular structures. sACE is formed by two
identical subunits, whereas tACE is formed by a single subunit [44–47] and both exhibit comparable
enzymatic activity [6]. The transcription of the testicular form is tissue-specific and occurs as a result
of alternative splicing, alternative transcription initiation, and alternative polyadenylation [9,48,49].
The most notable differences between the isoforms are their locations; while tACE is present only in
male germ cells [9,50,51], being found in high concentrations during spermiogenesis [6,9], sACE is
expressed in other testicular cells, such as Leydig cells and endothelial cells of the testicular interstitial
tissue [9], and in a soluble form in seminal plasma [42]. Although the concentration of sACE in the
testes is among the highest in all organs the specific role of sACE in the testes remains unknown.
sACE-deficient mice are fertile and the testes might be the sources of this enzyme in seminal fluid [6],
where it protects sperm during and after transfer to females [52].
The Ang II peptide is present in both germ cells [35] and in Leydig cells [41]. The presence of a
blood-testicular barrier, together with the fact that all the components necessary for the production of
this protein (renin, ACE, AGT and Ang I) are found within Leydig cells, supports the intracellular
synthesis of this peptide. Ang II has been reported to be capable of inhibiting adenylate cyclase
activity in rat Leydig cells, reducing basal and gonadotropin-stimulated cAMP and testosterone
production [53,54]. On the other hand, it has also been proposed that Ang II may play a role in
testicular growth and/or differentiation [55]. Finally, the Ang II receptors AT1R and AT2R have also
been detected in rat, monkey and human testes, specifically in Leydig cells [53,56,57]. However,
the protein levels of both receptors, as well as the levels of their respective mRNAs, depend on age;
for example, the expression of AT2R predominates in the first days of life but gradually decreases
until the fourth week of life, leaving AT1R to be almost exclusively expressed [40]. It is unknown
whether these receptors play a role in the regulation of testicular formation [6]. Notably, two subtypes
of AT1R, AT1AR and AT1BR, have been described in the testes of mice but not in those of humans,
although no specific functions have been established for either of these subtypes [21]. The presence of
AT1R has also been observed in rat and human seminiferous tubules, specifically in sperm cells at
different maturation stages (spermatogonia and spermatids), suggesting that this receptor could be
involved in spermatogenesis [57]. Finally, Ang II, through its binding to AT1R, may interfere with
testosterone production [55].
Additional studies have shown that Ang II is transformed into Ang III by the action of APA,
after which Ang III exerts its action by binding to AT1R and AT2R [6,10]. The APA enzyme has been
detected in rat testis homogenates, showing high enzymatic activity. It has been proposed that this
enzyme, like Ang II, is involved in inhibiting steroidogenesis through production of Ang III and
activation of AT1R [58].
Taken together, these findings affirm that this canonical axis modulates steroidogenesis. Specifically,
Ang II and III, through binding to AT1R, negatively regulate testosterone production. Moreover,
AT1R may be involved in the spermatogenesis process. Although future studies are necessary, it has
been suggested a positive regulation of steroidogenesis through the AT2R, considering the contrasting
effects of AT1R and AT2R.
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Table 1. Regulation of the testicular function by local RAS.
Axis Component Function References
Renin/ACE/Ang II/
AT1R/AT2R axis
AGT Local production of Ang II Dzau et al. 1987, Speth et al. 1999







Dufau et al. 1989,
Khanum and Dufau 1988
Schunkert et al. 1993;
Leung and Sernia 2003
Hirai et al. 1998
Ang III Negative regulation oftestosterone production
de la Chica-Rodriguez et al. 2008,





Vinson et al. 1995
Hirai et al. 1998








Reis et al. 2010






Alenina et al. 2002,
Leal et al. 2009, Xu et al. 2007











Erdos et al., 1985
Ang IV
AT4R-IRAP axis
Ang IV Negative regulation oftestosterone production
de la Chica-Rodriguez et al. 2008,







Osada et al. 2001
Martinez-Martos et al. 2011
APB Negative regulation oftestosterone production Martinez-Martos et al. 2011
(Pro)renin/
PRR axis
(Pro)renin Positive regulation ofspermatogenesis Mukhopadhyay et al. 1995
Renin Positive regulation oftestosterone production Parmentier et al. 1983
3.1.2. The ACE2/Ang (1–7)/MasR Axis
All the principal components of the axis ACE2/Ang (1–7)/ MasR have been detected in rat, mouse,
and human testes [32]. Single-cell RNA sequencing data on human testes showed predominant
expression of ACE2 in spermatogonia, Leydig and Sertoli cells [59], but ACE2 has been found to be
localized only in Leydig cells at the protein level [60,61]. Although Ace2-null mice are fertile [62],
men with severely impaired spermatogenesis have lower levels of ACE2 than fertile men, suggesting
that this enzyme may modulate sperm formation [32]. ACE2 has also been reported to play key roles
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in the regulation of testosterone production and in the local vascular regulatory system, in which it
balances interstitial fluid volume by modulating the conversion of Ang II to Ang I [52]. Ang (1–7) has
also been identified and characterized in mouse [61,63], rat [63] and human testes [32], in the cytoplasm
of Leydig cells, and in Sertoli cells and primary spermatocytes at lower levels [32]. This heptapeptide
is involved in the regulation of spermatogenesis, since lower levels of Ang-(1–7) have been found
in men with severe spermatogenesis impairment than in fertile men [32]. Similar to this peptide,
MasR has been described to be present in the cytoplasm of mouse [60,63], human Leydig cells
and inside the human seminiferous tubules in all layers of the normal seminiferous epithelium,
being equally distributed between interstitial and tubular compartments [32]. However, its mRNA
has been detected in both Leydig and Sertoli cells, with its expression being more pronounced in the
latter, but not in developing germ cells [60]. Concerning MasR function, MasR-deficient mice have
constitutive alterations in the activity of genes encoding steroidogenic enzymes within the testes [60,64].
This finding and the observation that MasR and Ang-(1–7) are present in Leydig cells, suggest that
both MasR and Ang-(1–7) could play a key role in modulating the production of testosterone [32].
Notably, it has been reported that MasR-deficient mice show marked reductions in testis weight,
a significant increase of apoptotic cells during meiosis, the presence of giant cells and vacuoles in
the seminiferous epithelium, and striking reductions in daily sperm production due to disturbed
spermatogenesis [63,65], although the total numbers of Sertoli and Leydig cells are comparable in both
wild-type and knockout animals [65]. Moreover, MasR levels are notably decreased or absent under
conditions of severe spermatogenesis alteration in humans, providing insights into the role of the MasR
in the regulation of spermatogenesis [32].
Although there are no data in the literature that specifically show the presence of Ang (1–9)
in the testes, the presence of Ang I and Ang (1–7), as well as the enzymes ACE, ACE2 and NEP,
could indicate that this peptide is present in this tissue [6,7]. On the other hand, NEP has been detected
in human testes [66] and in the membranes of rat Sertoli cells [67], and its activity is low in testicular
homogenate [66] but high in Sertoli cells [67]. It has been suggested that this metalloendopeptidase
may be related to sperm maturation and proacrosin activation [66]. Nevertheless, NEP-deficient mice
have normal testicular function [68]. Similarly, an isoform of this enzyme, NEP2, has been observed in
mouse [69] and human testes [70]. Studies have also demonstrated the presence of NEP2 mRNA in the
seminiferous tubules, specifically in developing germ cells and mainly in spermatids [71]. However,
the concrete function of NEP2 in the testes remains unknown.
Taken together, these data clearly indicate that this axis plays key roles in regulating steroidogenesis
and spermatogenesis (Table 1).
3.1.3. The Ang IV/AT4R-IRAP Axis
This pathway begins with the action of APN or APB. The metallopeptidase APN has been
localized in both human [72] and mouse testes, showing high gene expression in Sertoli and Leydig
cells [73]. APN seems to play a role in the inhibition of testosterone synthesis [74]. In fact, mice lacking
APN present defects in spermatogenesis and infertility, as they have altered Sertoli cell function [73].
In addition, APB has been detected in mouse testes, and it also participates in inhibition of the synthesis
of this hormone [74] (Table 1).
Although the specific function of Ang IV in the testes remains unknown, Ang IV could also be
involved in inhibition of testicular testosterone production [58,74]. Likewise, although the presence of
AT4R/IRAP in the testes has not yet been described, the presence of the other components of this axis
could indicate that this receptor is present in this tissue. Despite the scarcity of evidence regarding the
presence and functions of the main members of Ang IV/AT4R-IRAP axis in the testes, the available
data show how this axis is also related to inhibition of testicular testosterone production and, therefore,
in the regulation of spermatogenesis.
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3.1.4. The (Pro)renin/PRR Axis
Prorenin is known to be produced and secreted by the testes [75] and it has been found a correlation
between sperm density and the prorenin level in semen [76]. Similarly, it has been shown that Leydig
cells are capable of producing renin [6,34,40] and that renin levels are directly related to testicular
testosterone concentrations [38]. Thus, it could be hypothesized that this axis is positively involved in
steroidogenesis (Table 1). Nonetheless, as previously described, the (pro)renin/PRR axis was described
after the existence of the PRR was discovered [12]. No evidence has yet been reported showing that this
receptor is present in the testes; therefore, further studies should be performed in order to demonstrate
the presence of PRR and consequently the existence of this axis as well as to understand the functional
role of prorenin and/or renin independent of the effects of the classical RAS cascade.
3.2. Regulation of Sperm Phisiology by Local RAS
In order to acquire fertilization ability, spermatozoa must undergo a series of processes,
such as motility acquisition; capacitation; the acrosomal reaction; and oocyte recognition, fusion
and activation [77]. These processes must be perfectly regulated to ensure proper development. It is
known that tight control is exerted by the joint actions of complex biological systems, including the
RAS [21,40,77]. Accumulated evidence regarding the presence, distributions and specific functions
of different members of this peptide system in sperm cells suggests that the RAS regulates male
reproductive function by acting directly on the fertility potential of spermatozoa [8]. In addition, as has
been observed for testicular function, the different RAS axes could exert opposite roles, which would
result in fine modulation of reproductive function (Table 2).
Table 2. Regulation of the sperm physiology by local RAS.
Axis Component Function References
Renin/ACE/Ang II/
AT1R/AT2R axis








Siems et al. 1991,
Yamaguchi et al. 2006,
Foresta et al. 1987, Kohn et al. 1995,
Hagaman et al. 1998,
Krege et al. 1995, Foresta et al. 1991,
Gianzo et al. 2018,
Gianzo et al. 2018





Foresta et al. 1991, Kohn et al. 1995,
Sabeur et al. 2000, Vinson et al. 1996,
Wennemuth et al. 1999
AT1R Regulation ofsperm motility Vinson et al. 1996
AT2R Regulation ofsperm motility Gianzo et al., 2016
ACE2/Ang (1–7)/
MasR axis
Ang-(1–7) Positive regulation ofsperm motility Valdivia et al. 2020
MasR Regulation ofsperm motility Valdivia et al. 2020







Carpentier et al. 2004
Pinto et al. 2010
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Table 2. Cont.









Togo and Morisawa 1997,
Togo and Morisawa 2004
Subiran et al. 2008,
Irazusta et al. 2004




sperm motility Gianzo et al. (Unpublished data)
3.2.1. The Renin/ACE/Ang II/AT1R/AT2R Axis
Members of the Renin/ACE/Ang II/AT1R/AT2R are present in seminal fluid and sperm cells,
where they may have different putative effects. High levels of renin and Ang II are present in seminal
plasma [27,78]; although they have not yet been specifically detected in sperm cells. sACE has also
been observed in seminal plasma at higher concentrations than in blood plasma and it is positively
correlated with sperm concentration and motility [40,76], although oligospermic patients have sACE
levels similar to those of normozoospermic men [79]. Even though AGT has not been described in
spermatozoa, it plays a key role in the function of these cells, since Agt-deficient male mice show
reduced fertility, as their sperm cells are less likely to fertilize oocytes than those of wild-type mice [80].
On the other hand, other RAS members, such as tACE, Ang II, and Ang II receptors, have been
specifically detected in germinal cells. Specifically, tACE is present in spermatids and mature sperm
of different species [81–83], being located mainly in the acrosomal region, the equatorial segment,
the postacrosomal region and the intermediate piece of sperm cells [84,85]. Although tACE enzymatic
activity is low in immature rats, it increases with sexual maturity, suggesting that its presence is
dependent on sexual maturation [51,86–90]. Moreover, different studies have demonstrated the
involvement of tACE in sperm motility [90–93], capacitation [87,89], the acrosome reaction [89] and
sperm-oocyte fusion [88]. Interestingly, the levels of tACE on the sperm surface differ during different
phases of the fertilization process because tACE is released during capacitation [87,89] and the acrosome
reaction [89]. It has been supposed that this release may have a physiological role in the regulation of
sperm physiology as well as in sperm fertilization ability [88]. In this sense, the lack of sACE in male mice
does not affect fertility, while animals lacking both ACE isoforms show reduced fertility due to failure
of spermatozoa transport through the oviduct and gamete fusion [94,95]. On the other hand, tACE has
been proposed to be an essential protein in the sperm-oocyte fusion process [96], although specific
tACE3-IZUMO1 binding is not required for oocyte fertilization [52]. In addition, patients enrolled in
in vitro fertilization (IVF) programmes found that aberrant, reduced or absent expression of the tACE
protein on sperm underlies failed fertilization [51], and it is also involved in embryo development,
since higher percentages of tACE-positive cells and fewer enzyme molecules per spermatozoon in
semen samples are positively correlated with better embryo quality and development [93].
Ang II has been widely studied in sperm cells and both Ang II receptors, AT1R and AT2R,
have been identified in sperm cells. Ang II is evidently a key modulator of sperm function given
that this peptide is involved in sperm motility, capacitation, and the acrosomal reaction [88,89,97–99].
AT1R has been detected in developing spermatids and mature spermatozoa in humans and other
mammalian species [33,98–101] and is located in the tails of human sperm [100]. Targeted deletion of
the AT1BR gene (Agtr1b) in mice results in high AT1BR transcriptional activity in mature and immature
sperm cells [6]. Treatment with antagonists of ATIR receptor (losartan) inhibits sperm motility and
Ang I and II increases not only the percentage of motile spermatozoa but also the linear velocities of
the spermatozoa, which proves that AT1R is involved in sperm motility [97]. AT2R has been described
in mouse [98] and human spermatozoa [33], and it may play also an important role in sperm motility,
as it has been observed that AT2R is related to human sperm concentration and motility, and the
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percentage of AT2R-positive spermatozoa is lower in asthenozoospermic patients (sperm samples with
suboptimal motility) than in normozoospermic males [33].
In conclusion, this canonical axis plays a key role in the proper functioning of sperm cells since
it is involved in physiological processes such as sperm motility, capacitation, the acrosome reaction,
and sperm-egg recognition and fusion (Table 2).
3.2.2. The ACE2/Ang (1–7)/MasR Axis
Few studies describe the presence and function of the ACE2/Ang (1–7)/MasR axis in spermatozoa.
Although the presence of ACE2 in sperm cells has not yet been demonstrated, several evidences indicate
the existence and/or action of the other main members of this signalling pathway, such as Ang 1–7
and MasR (Table 2). Even though Ang (1–7) has not been localized in mature spermatozoa [32,102],
incubation of seminal samples from asthenozoospermic patients with this peptide increases the
proportion of progressive motile spermatozoa through MasR signalling [102]. In addition, in the
sperm of asthenozoospermic patients, Ang-(1–7) may exert some effects independent of MasR, perhaps
through binding to receptors such as the MRGPRD receptor (a GPCR related to MasR) or AT2R [102].
With reference to the specific receptor, it has been observed that MasR is present in human mature
spermatozoa at the mRNA and protein levels [32,102]. MasR is located in the human sperm head,
with the highest levels at the acrosomal region, but also in the tail. In addition, this receptor is
functional, and its activation participates in regulating sperm motility [102].
The presence of another enzyme in this non-canonical RAS axis, NEP, has also been broadly proved.
In fact, this endopeptidase has been located at higher concentrations and with stronger enzymatic
activity in human seminal fluid than in other body tissues [28]. It has also been detected at the gene and
protein levels in sperm cells; it is located in the neck in a small proportion of human spermatozoa [103].
Congruent with its location, this enzyme participates in the regulation of sperm motility, since its
inhibition improves the motility of capacitated spermatozoa, increasing the percentage of sperm with
progressive motility [103]. Moreover, NEP activity is altered in asthenozoospermic patients compared
to normozoospermic men [29]. Likewise, the NEP-homologous enzyme NEP2 [69] has been described
to be present around the equatorial segment in human spermatozoa, and its selective inhibition
with phosphoramidon increases sperm progressive motility [71]. However, the effects observed after
inhibition of both neprilysins are mediated, at least in part, by tachykinins [71]. In addition, animal
studies have shown that NEP2-deficient mice exhibit less efficient egg fertilization than wild-type mice
and that large proportions of oocytes do not develop normally after fertilization with NEP2-null mouse
spermatozoa [68].
3.2.3. The Ang IV/AT4R-IRAP Axis
The all components of the Ang IV/AT4R-IRAP axis have not yet been detected in spermatozoa.
In spite of that, presence of APN, the enzyme responsible for the formation of the Ang IV peptide,
could indicate that both this peptide and its receptor are present in these cells. APN is present in
human seminal fluid [28] and exhibits significantly higher activity and concentrations in seminal
fluid than in other body tissues [28]. In sperm, this enzyme has also been detected at the gene and
protein levels; it is located at the plasma membrane of the equatorial/postacrosomal region of the
sperm head, in the neck and uniformly distributed along the tail [103]. In mussel spermatozoa,
this enzyme induces the acrosome reaction [104,105]. Moreover, APN has been negatively related to
sperm motility [31,103,106,107], and its activity is altered in asthenozoospermic patients compared to
normozoospermic men [29] (Table 2). Moreover, the alteration in APN activity induces cellular toxicity
in sperm cells, which causes persistent damage [29,106] and produces several adverse consequences
and affecting early embryonic development in mice [106,107]. These findings are consistent with the
fact that the cumulative probabilities of having developed blastocysts and viable embryos increase by
1.5-fold when semen samples with relatively low APN levels are used during the intracytoplasmic
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sperm injection (ICSI) technique (Gianzo et al., unpublished data). Strong evidences, therefore, indicate
that APN play a key role in sperm fertility ability.
3.2.4. The (pro)renin/PRR axis
Large amounts of renin and its precursor, prorenin, have been detected in human seminal
fluid [76,78]. However, the putative effects of these molecules on the physiology of spermatozoa have
not yet been clarified. As previously indicated, the presence of PRR is essential for the existence of
the (pro)renin/PRR axis [12]. In addition, we have recently described the presence of PRR in human
spermatozoa at the gene and protein levels and this receptor seems to play a role in sperm motility
(Gianzo et al., unpublished data). PRR is located mainly in the proximal region over the acrosome
and in the postacrosomal region of the head; to a lesser extent, it also extends along the sperm tail.
Given these novel data, along with the high concentrations of renin and its precursor, prorenin,
observed in human seminal fluid [76,78], it can be assumed that this non canonical axis could be
important in the regulation of sperm functions (Table 2).
4. Conclusions and Perspectives
The descriptions of different elements in the canonical and non-canonical enzymatic RAS pathways
in the male reproductive system indicate that both pathways may be actively present, regulating
male fertility by paracrine and autocrine mechanisms. In the testes, several RAS components are
present in Leydig, Sertoli and spermatogenic cells at different maturation stages, indicating that these
elements can modulate testosterone production and spermatogenesis. RAS functions at the seminal
level are involved in the regulation of essential processes of male fertility, such as motility acquisition,
the acrosomal reaction, oocyte fertilization, and early embryonic development. However, even more
interestingly, certain elements of these RAS axes, such as tACE, AT2R and APN, can aid in the diagnosis
and treatment of human male fertility by acting as potential biomarkers of high-quality embryos,
providing added value in the pursuit of male fertility prognosis.
Even though many functions of the RAS in male fertility are clear, numerous other relevant aspects
of the male reproductive system remain unknown, such as (1) whether all elements of the RAS are
present in testes, sperm and seminal fluid and the functions that they exert in these tissues; (2) whether
the various components play important roles in the regulation and/or formation of testes; (3) whether
the various RAS elements found in the seminal fluid play roles relevant to the survival and/or transport
of sperm through the female reproductive tract; and (4) whether the levels of these components could
vary under different pathological conditions. A more complete knowledge of the overall function of
the RAS in the male reproductive system could improve understanding of this system in sperm and in
male fertility-related physiology and physiopathology. Likewise, elucidation of RAS function could
support the development of new diagnostic tools or therapeutic strategies for male infertility and
the establishment of useful biomarkers for the selection of optimal spermatozoa for use in assisted
reproduction techniques.
Author Contributions: Writing—Original Draft Preparation, M.G.; Writing—Review & Editing, N.S. All authors
have read and agreed to the published version of the manuscript.
Funding: This study was supported by grants from the Basque Government (GIC12/173) and University of the
Basque Country (UPV/EHU) (EHUA14/17).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Krausz, C.; Escamilla, A.E.; Cianese, C. Genetics of male infertility: From research to clinic. Reproduction
2015, 150, R159–R174. [CrossRef]
2. Samplaski, M.K.; Agarwal, A.; Sharma, R.; Sabanegh, E. New Generation of Diagnostic Tests for Infertility:
Review of Specialized Semen Tests. Int. J. Urol. 2010, 17, 839–847. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 7943 13 of 18
3. Jamsai, D.; O’Bryan, M.K. Mouse Models in Male Fertility Research. Asian J. Androl. 2011, 13, 139–151.
[CrossRef] [PubMed]
4. Huleihel, M.; Lunenfeld, E. Regulation of Spermatogenesis by paracrine/autocrine Testicular Factors. Asian J.
Androl. 2004, 6, 259–268. [PubMed]
5. Pandey, A.; Flueck, C. Testicular Steroidogenesis. In Endocrinology of the Testis and Male Reproduction;
Simoni, M., Huhtaniemi, I.T., Eds.; Springer: Berlin/Heidelberg, Germany, 2017; pp. 1–29.
6. Paul, M.; Poyan Mehr, A.; Kreutz, R. Physiology of Local Renin-Angiotensin Systems. Physiol. Rev. 2006, 86,
747–803. [CrossRef]
7. Herr, D.; Bekes, I.; Wulff, C. Local Renin-Angiotensin System in the Reproductive System. Front. Endocrinol.
2013, 4, 150. [CrossRef]
8. Leung, P.S.; Sernia, C. The Renin-Angiotensin System and Male Reproduction: New Functions for Old
Hormones. J. Mol. Endocrinol. 2003, 30, 263–270. [CrossRef]
9. Pauls, K.; Metzger, R.; Steger, K.; Klonisch, T.; Danilov, S.; Franke, F.E. Isoforms of Angiotensin I-Converting
Enzyme in the Development and Differentiation of Human Testis and Epididymis. Andrologia 2003, 35, 32–43.
[CrossRef]
10. De Gasparo, M.; Catt, K.J.; Inagami, T.; Wright, J.W.; Unger, T. International Union of Pharmacology. XXIII.
The Angiotensin II Receptors. Pharmacol. Rev. 2000, 52, 415–472.
11. George, A.J.; Thomas, W.G.; Hannan, R.D. The Renin-Angiotensin System and Cancer: Old Dog, New Tricks.
Nat. Rev. Cancer 2010, 10, 745–759. [CrossRef]
12. Nguyen, G.; Delarue, F.; Burckle, C.; Bouzhir, L.; Giller, T.; Sraer, J.D. Pivotal Role of the renin/prorenin
Receptor in Angiotensin II Production and Cellular Responses to Renin. J. Clin. Investig. 2002, 109, 1417–1427.
[CrossRef] [PubMed]
13. Fyhrquist, F.; Saijonmaa, O. Renin-Angiotensin System Revisited. J. Intern. Med. 2008, 264, 224–236.
[CrossRef] [PubMed]
14. Re, R.N. Intracellular Renin and the Nature of Intracrine Enzymes. Hypertension 2003, 42, 117–122. [CrossRef]
[PubMed]
15. Kumar, R.; Singh, V.P.; Baker, K.M. The Intracellular Renin-Angiotensin System: A New Paradigm.
Trends Endocrinol. Metab. 2007, 18, 208–214. [CrossRef] [PubMed]
16. Chappell, M.C.; Marshall, A.C.; Alzayadneh, E.M.; Shaltout, H.A.; Diz, D.I. Update on the Angiotensin Converting
Enzyme 2-Angiotensin (1–7)-Mas Receptor Axis: Fetal Programing, Sex Differences, and Intracellular Pathways.
Front. Endocrinol. 2014, 4. [CrossRef]
17. Vinson, G.P.; Saridogan, E.; Puddefoot, J.R.; Djahanbakhch, O. Tissue Renin-Angiotensin Systems and
Reproduction. Hum. Reprod. 1997, 12, 651–662. [CrossRef] [PubMed]
18. Castilho, A.C.; Fontes, P.K.; Franchi, F.F.; Santos, P.H.; Razza, E.M. Renin-Angiotensin System on Reproductive
Biology. In Renin-Angiotensin System; Fontes, P.K., Ed.; IntechOpen: Rijeka, Croatia, 2017; p. 5.
19. Iwai, M.; Horiuchi, M. Devil and Angel in the Renin-Angiotensin System: ACE-Angiotensin II-AT1 Receptor
Axis Vs. ACE2-Angiotensin-(1–7)-Mas Receptor Axis. Hypertens. Res. 2009, 32, 533–536. [CrossRef] [PubMed]
20. Santos, R.A.; Ferreira, A.J.; Verano-Braga, T.; Bader, M. Angiotensin-Converting Enzyme 2, Angiotensin-(1–7)
and Mas: New Players of the Renin-Angiotensin System. J. Endocrinol. 2013, 216, R1–R17. [CrossRef]
[PubMed]
21. Albiston, A.L.; McDowall, S.G.; Matsacos, D.; Sim, P.; Clune, E.; Mustafa, T.; Lee, J.; Mendelsohn, F.A.;
Simpson, R.J.; Connolly, L.M.; et al. Evidence that the Angiotensin IV (AT(4)) Receptor is the Enzyme
Insulin-Regulated Aminopeptidase. J. Biol. Chem. 2001, 276, 48623–48626. [CrossRef] [PubMed]
22. Nguyen, G. Renin, (Pro)Renin and Receptor: An Update. Clin. Sci. 2011, 120, 169–178. [CrossRef] [PubMed]
23. Leung, P.S.; Chan, H.C.; Fu, L.X.; Leung, P.Y.; Chew, S.B.; Wong, P.Y. Angiotensin II Receptors: Localization
of Type I and Type II in Rat Epididymides of Different Developmental Stages. J. Membr. Biol. 1997, 157,
97–103. [CrossRef] [PubMed]
24. Leung, P.S.; Wong, T.P.; Sernia, C. Angiotensinogen Expression by Rat Epididymis: Evidence for an Intrinsic,
Angiotensin-Generating System. Mol. Cell. Endocrinol. 1999, 155, 115–122. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 7943 14 of 18
25. Sum, C.S.; Cheung, W.T. Characterization of Contractile Response to Angiotensin in Epididymal Rat Vas
Deferens. Pharmacology 1995, 51, 105–111. [CrossRef]
26. Dinh, D.T.; Frauman, A.G.; Sourial, M.; Casley, D.J.; Johnston, C.I.; Fabiani, M.E. Identification, Distribution,
and Expression of Angiotensin II Receptors in the Normal Human Prostate and Benign Prostatic Hyperplasia.
Endocrinology 2001, 142, 1349–1356. [CrossRef]
27. O’Mahony, O.A.; Djahanbahkch, O.; Mahmood, T.; Puddefoot, J.R.; Vinson, G.P. Angiotensin II in Human
Seminal Fluid. Hum. Reprod. 2000, 15, 1345–1349. [CrossRef]
28. Fernandez, D.; Valdivia, A.; Irazusta, J.; Ochoa, C.; Casis, L. Peptidase Activities in Human Semen. Peptides
2002, 23, 461–468. [CrossRef]
29. Irazusta, J.; Valdivia, A.; Fernandez, D.; Agirregoitia, E.; Ochoa, C.; Casis, L. Enkephalin-Degrading Enzymes
in Normal and Subfertile Human Semen. J. Androl. 2004, 25, 733–739. [CrossRef]
30. Okuyama, A.; Nonomura, N.; Koh, E.; Kondoh, N.; Takeyama, M.; Nakamura, M.; Namiki, M.; Fujioka, H.;
Matsumoto, K.; Matsuda, M. Induction of Renin-Angiotensin System in Human Testis in Vivo. Arch. Androl.
1988, 21, 29–35. [CrossRef] [PubMed]
31. Subiran, N.; Pinto, F.M.; Agirregoitia, E.; Candenas, L.; Irazusta, J. Control of APN/CD13 and NEP/CD10 on
Sperm Motility. Asian J. Androl. 2010, 12, 899–902. [CrossRef]
32. Reis, A.B.; Araujo, F.C.; Pereira, V.M.; Dos Reis, A.M.; Santos, R.A.; Reis, F.M. Angiotensin (1–7) and its
Receptor Mas are Expressed in the Human Testis: Implications for Male Infertility. J. Mol. Histol. 2010, 41,
75–80. [CrossRef] [PubMed]
33. Gianzo, M.; Munoa-Hoyos, I.; Urizar-Arenaza, I.; Larreategui, Z.; Quintana, F.; Garrido, N.; Subiran, N.;
Irazusta, J. Angiotensin II Type 2 Receptor is Expressed in Human Sperm Cells and is Involved in Sperm
Motility. Fertil. Steril. 2016, 105, 608–616. [CrossRef]
34. Dzau, V.J.; Ellison, K.E.; Brody, T.; Ingelfinger, J.; Pratt, R.E. A Comparative Study of the Distributions of
Renin and Angiotensinogen Messenger Ribonucleic Acids in Rat and Mouse Tissues. Endocrinology 1987,
120, 2334–2338. [CrossRef] [PubMed]
35. Pandey, K.N.; Misono, K.S.; Inagami, T. Evidence for Intracellular Formation of Angiotensins: Coexistence of
Renin and Angiotensin-Converting Enzyme in Leydig Cells of Rat Testis. Biochem. Biophys. Res. Commun.
1984, 122, 1337–1343. [CrossRef]
36. Pandey, K.N.; Maki, M.; Inagami, T. Detection of Renin mRNA in Mouse Testis by Hybridization with Renin
cDNA Probe. Biochem. Biophys. Res. Commun. 1984, 125, 662–667. [CrossRef]
37. Deschepper, C.F.; Mellon, S.H.; Cumin, F.; Baxter, J.D.; Ganong, W.F. Analysis by Immunocytochemistry and
in Situ Hybridization of Renin and its mRNA in Kidney, Testis, Adrenal, and Pituitary of the Rat. Proc. Natl.
Acad. Sci. USA 1986, 83, 7552–7556. [CrossRef] [PubMed]
38. Parmentier, M.; Inagami, T.; Pochet, R.; Desclin, J.C. Pituitary-Dependent Renin-Like Immunoreactivity in
the Rat Testis. Endocrinology 1983, 112, 1318–1323. [CrossRef] [PubMed]
39. Naruse, M.; Naruse, K.; Shizume, K.; Inagami, T. Gonadotropin-Dependent Renin in the Rat Testes. Proc. Soc.
Exp. Biol. Med. 1984, 177, 337–342. [CrossRef] [PubMed]
40. Speth, R.C.; Daubert, D.L.; Grove, K.L. Angiotensin II: A Reproductive Hormone Too? Regul. Pept. 1999, 79,
25–40. [CrossRef]
41. Pandey, K.N.; Inagami, T. Regulation of Renin Angiotensins by Gonadotropic Hormones in Cultured Murine
Leydig Tumor Cells. Release of Angiotensin but Not Renin. J. Biol. Chem. 1986, 261, 3934–3938. [PubMed]
42. Cushman, D.W.; Cheung, H.S. Concentrations of Angiotensin-Converting Enzyme in Tissues of the Rat.
Biochim. Biophys. Acta Enzymol. 1971, 250, 261–265. [CrossRef]
43. Howard, T.; Balogh, R.; Overbeek, P.; Bernstein, K.E. Sperm-Specific Expression of Angiotensin-Converting
Enzyme (ACE) is Mediated by a 91-Base-Pair Promoter Containing a CRE-Like Element. Mol. Cell. Biol.
1993, 13, 18–27. [CrossRef]
44. Soubrier, F.; Alhenc-Gelas, F.; Hubert, C.; Allegrini, J.; John, M.; Tregear, G.; Corvol, P. Two Putative Active
Centers in Human Angiotensin I-Converting Enzyme Revealed by Molecular Cloning. Proc. Natl. Acad. Sci. USA
1988, 85, 9386–9390. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 7943 15 of 18
45. Ehlers, M.R.; Fox, E.A.; Strydom, D.J.; Riordan, J.F. Molecular Cloning of Human Testicular Angiotensin-
Converting Enzyme: The Testis Isozyme is Identical to the C-Terminal Half of Endothelial Angiotensin-
Converting Enzyme. Proc. Natl. Acad. Sci. USA 1989, 86, 7741–7745. [CrossRef]
46. Bernstein, K.E.; Martin, B.M.; Edwards, A.S.; Bernstein, E.A. Mouse Angiotensin-Converting Enzyme is a
Protein Composed of Two Homologous Domains. J. Biol. Chem. 1989, 264, 11945–11951.
47. Hubert, C.; Houot, A.M.; Corvol, P.; Soubrier, F. Structure of the Angiotensin I-Converting Enzyme Gene.
Two Alternate Promoters Correspond to Evolutionary Steps of a Duplicated Gene. J. Biol. Chem. 1991, 266,
15377–15383.
48. Howard, T.E.; Shai, S.Y.; Langford, K.G.; Martin, B.M.; Bernstein, K.E. Transcription of Testicular
Angiotensin-Converting Enzyme (ACE) is Initiated within the 12th Intron of the Somatic ACE Gene.
Mol. Cell. Biol. 1990, 10, 4294–4302. [CrossRef]
49. Langford, K.G.; Shai, S.Y.; Howard, T.E.; Kovac, M.J.; Overbeek, P.A.; Bernstein, K.E. Transgenic Mice
Demonstrate a Testis-Specific Promoter for Angiotensin-Converting Enzyme. J. Biol. Chem. 1991, 266,
15559–15562.
50. Velletri, P.A. Testicular Angiotensin I-Converting Enzyme (E.C. 3.4.15.1). Life Sci. 1985, 36, 1597–1608.
[CrossRef]
51. Li, L.J.; Zhang, F.B.; Liu, S.Y.; Tian, Y.H.; Le, F.; Wang, L.Y.; Lou, H.Y.; Xu, X.R.; Huang, H.F.; Jin, F. Human
Sperm Devoid of Germinal Angiotensin-Converting Enzyme is Responsible for Total Fertilization Failure
and Lower Fertilization Rates by Conventional in Vitro Fertilization. Biol. Reprod. 2014, 90, 125. [CrossRef]
52. Pan, P.P.; Zhan, Q.T.; Le, F.; Zheng, Y.M.; Jin, F. Angiotensin-Converting Enzymes Play a Dominant Role in
Fertility. Int. J. Mol. Sci. 2013, 14, 21071–21086. [CrossRef]
53. Khanum, A.; Dufau, M.L. Angiotensin II Receptors and Inhibitory Actions in Leydig Cells. J. Biol. Chem.
1988, 263, 5070–5074. [PubMed]
54. Dufau, M.L.; Ulisse, S.; Khanum, A.; Buczko, E.; Kitamura, M.; Fabbri, A.; Namiki, M. LH Action in the
Leydig Cell: Modulation by Angiotensin II and Corticotropin Releasing Hormone, and Regulation of P450(17)
Alpha mRNA. J. Steroid Biochem. 1989, 34, 205–217. [CrossRef]
55. Hirai, K.; Song, K.; Kanehara, H.; Shiota, N.; Ueda, H.; Kim, S.; Miyazaki, H.; Katsuoka, Y.; Miyazaki, M.
Pituitary-Dependent Expression of the Testicular Angiotensin II Receptor and its Subtypes in Rats. Int. J.
Androl. 1998, 21, 177–185. [CrossRef] [PubMed]
56. Millan, M.A.; Aguilera, G. Angiotensin II Receptors in Testes. Endocrinology 1988, 122, 1984–1990. [CrossRef]
57. Vinson, G.P.; Ho, M.M.; Puddefoot, J.R. The Distribution of Angiotensin II Type 1 Receptors, and the Tissue
Renin-Angiotensin Systems. Mol. Med. Today 1995, 1, 35–39. [CrossRef]
58. De la Chica-Rodriguez, S.; Cortes-Denia, P.; Ramirez-Exposito, M.J.; de Saavedra, J.M.; Sanchez-Agesta, R.;
Perez Mdel, C.; Martinez-Martos, J.M. In Vivo Administration of Doxazosin in Rats Highly Decreases Serum
Circulating Levels of Testosterone through a Mechanism Involving the Testicular Renin-Angiotensin System.
Int. J. Androl. 2008, 31, 364–370. [CrossRef]
59. Wang, Z.; Xu, X. ScRNA-Seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target
for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. Cells 2020, 9, 920. [CrossRef]
60. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.;
Robison, K.; Jeyaseelan, R.; et al. A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase
(ACE2) Converts Angiotensin I to Angiotensin 1–9. Circ. Res. 2000, 87, E1–E9. [CrossRef] [PubMed]
61. Alenina, N.; Baranova, T.; Smirnow, E.; Bader, M.; Lippoldt, A.; Patkin, E.; Walther, T. Cell Type-Specific
Expression of the Mas Proto-Oncogene in Testis. J. Histochem. Cytochem. 2002, 50, 691–696. [CrossRef]
62. Crackower, M.A.; Sarao, R.; Oudit, G.Y.; Yagil, C.; Kozieradzki, I.; Scanga, S.E.; Oliveira-dos-Santos, A.J.;
da Costa, J.; Zhang, L.; Pei, Y.; et al. Angiotensin-Converting Enzyme 2 is an Essential Regulator of Heart
Function. Nature 2002, 417, 822–828. [CrossRef]
63. Leal, M.C.; Pinheiro, S.V.; Ferreira, A.J.; Santos, R.A.; Bordoni, L.S.; Alenina, N.; Bader, M.; Franca, L.R.
The Role of Angiotensin-(1–7) Receptor Mas in Spermatogenesis in Mice and Rats. J. Anat. 2009, 214, 736–743.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 7943 16 of 18
64. Xu, P.; Santos, R.A.; Bader, M.; Alenina, N. Alterations in Gene Expression in the Testis of Angiotensin-(1–7)-
Receptor Mas-Deficient Mice. Regul. Pept. 2007, 138, 51–55. [CrossRef] [PubMed]
65. Walther, T.; Balschun, D.; Voigt, J.P.; Fink, H.; Zuschratter, W.; Birchmeier, C.; Ganten, D.; Bader, M. Sustained
Long-Term Potentiation and Anxiety in Mice Lacking the Mas Protooncogene. J. Biol. Chem. 1998, 273,
11867–11873. [CrossRef] [PubMed]
66. Erdos, E.G.; Schulz, W.W.; Gafford, J.T.; Defendini, R. Neutral Metalloendopeptidase in Human Male Genital
Tract. Comparison to Angiotensin I-Converting Enzyme. Lab. Investig. J. Tech. Methods Pathol. 1985, 52,
437–447.
67. Monsees, T.K.; Gornig, M.; Schill, W.B.; Miska, W. Possible Involvement of Proteases in the Regulation of
Spermatogenesis. Andrologia 1998, 30, 185–191. [CrossRef] [PubMed]
68. Carpentier, M.; Guillemette, C.; Bailey, J.L.; Boileau, G.; Jeannotte, L.; DesGroseillers, L.; Charron, J. Reduced
Fertility in Male Mice Deficient in the Zinc Metallopeptidase NL1. Mol. Cell. Biol. 2004, 24, 4428–4437.
[CrossRef] [PubMed]
69. Ghaddar, G.; Ruchon, A.F.; Carpentier, M.; Marcinkiewicz, M.; Seidah, N.G.; Crine, P.; Desgroseillers, L.;
Boileau, G. Molecular Cloning and Biochemical Characterization of a New Mouse Testis Soluble-Zinc-
Metallopeptidase of the Neprilysin Family. Biochem. J. 2000, 347, 419–429. [CrossRef]
70. Bonvouloir, N.; Lemieux, N.; Crine, P.; Boileau, G.; DesGroseillers, L. Molecular Cloning, Tissue Distribution,
and Chromosomal Localization of MMEL2, a Gene Coding for a Novel Human Member of the Neutral
Endopeptidase-24.11 Family. DNA Cell Biol. 2001, 20, 493–498. [CrossRef]
71. Pinto, F.M.; Ravina, C.G.; Subiran, N.; Cejudo-Roman, A.; Fernandez-Sanchez, M.; Irazusta, J.; Garrido, N.;
Candenas, L. Autocrine Regulation of Human Sperm Motility by Tachykinins. Reprod. Biol. Endocrinol. 2010,
8, 104. [CrossRef]
72. Huang, K.; Takahara, S.; Kinouchi, T.; Takeyama, M.; Ishida, T.; Ueyama, H.; Nishi, K.; Ohkubo, I. Alanyl
Aminopeptidase from Human Seminal Plasma: Purification, Characterization, and Immunohistochemical
Localization in the Male Genital Tract. J. Biochem. 1997, 122, 779–787. [CrossRef]
73. Osada, T.; Watanabe, G.; Kondo, S.; Toyoda, M.; Sakaki, Y.; Takeuchi, T. Male Reproductive Defects Caused
by Puromycin-Sensitive Aminopeptidase Deficiency in Mice. Mol. Endocrinol. 2001, 15, 960–971. [CrossRef]
74. Martinez-Martos, J.M.; Arrazola, M.; Mayas, M.D.; Carrera-Gonzalez, M.P.; Garcia, M.J.; Ramirez-Exposito, M.J.
Diet-Induced Hypercholesterolemia Impaired Testicular Steroidogenesis in Mice through the Renin-
Angiotensin System. Gen. Comp. Endocrinol. 2011, 173, 15–19. [CrossRef]
75. Sealey, J.E.; Goldstein, M.; Pitarresi, T.; Kudlak, T.T.; Glorioso, N.; Fiamengo, S.A.; Laragh, J.H. Prorenin
Secretion from Human Testis: No Evidence for Secretion of Active Renin or Angiotensinogen. J. Clin.
Endocrinol. Metab. 1988, 66, 974–978. [CrossRef] [PubMed]
76. Mukhopadhyay, A.K.; Cobilanschi, J.; Schulze, W.; Brunswig-Spickenheier, B.; Leidenberger, F.A. Human
Seminal Fluid Contains Significant Quantities of Prorenin: Its Correlation with the Sperm Density. Mol. Cell.
Endocrinol. 1995, 109, 219–224. [CrossRef]
77. Yoshida, M.; Kawano, N.; Yoshida, K. Control of Sperm Motility and Fertility: Diverse Factors and Common
Mechanisms. Cell Mol. Life Sci. 2008, 65, 3446–3457. [CrossRef] [PubMed]
78. Craven, D.J.; Warren, A.Y.; Symonds, E.M. Active and Inactive Renin in Human Seminal Plasma. Arch. Androl.
1981, 7, 63–67. [CrossRef]
79. Hohlbrugger, G.; Pschorr, J.; Dahlheim, H. Angiotensin I Converting Enzyme in the Ejaculate of Fertile and
Infertile Men. Fertil. Steril. 1984, 41, 324–325. [CrossRef]
80. Tempfer, C.B.; Moreno, R.M.; Gregg, A.R. Genetic Control of Fertility and Embryonic Waste in the Mouse:
A Rolefor Angiotensinogen. Biol. Reprod. 2000, 62, 457–462. [CrossRef]
81. Vanha-Perttula, T.; Mather, J.P.; Bardin, C.W.; Moss, S.B.; Bellve, A.R. Localization of the Antigotensin-
Converting Enzyme Activity in Testis and Epididymis. Biol. Reprod. 1985, 33, 870–877. [CrossRef] [PubMed]
82. Brentjens, J.R.; Matsuo, S.; Andres, G.A.; Caldwell, P.R.; Zamboni, L. Gametes Contain Angiotensin
Converting Enzyme (Kininase II). Experientia 1986, 42, 399–402. [CrossRef]
83. Dobrinski, I.; Ignotz, G.G.; Fagnan, M.S.; Yudin, S.I.; Ball, B.A. Isolation and Characterization of a Protein
with Homology to Angiotensin Converting Enzyme from the Periacrosomal Plasma Membrane of Equine
Spermatozoa. Mol. Reprod. Dev. 1997, 48, 251–260. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 7943 17 of 18
84. Ganong, W.F. Reproduction and the Renin-Angiotensin System. Neurosci. Biobehav. Rev. 1995, 19, 241–250.
[CrossRef]
85. Kohn, F.M.; Dammshauser, I.; Neukamm, C.; Renneberg, H.; Siems, W.E.; Schill, W.B.; Aumuller, G.
Ultrastructural Localization of Angiotensin-Converting Enzyme in Ejaculated Human Spermatozoa.
Hum. Reprod. 1998, 13, 604–610. [CrossRef] [PubMed]
86. Singh, U.S.; Kumar, M.V.; Panda, J.N. Angiotensin Converting Enzyme in Semen and its Possible Role in
Capacitation. Andrologia 1985, 17, 472–475. [CrossRef] [PubMed]
87. Foresta, C.; Indino, M.; Manoni, F.; Scandellari, C. Angiotensin-Converting Enzyme Content of Human
Spermatozoa and its Release during Capacitation. Fertil. Steril. 1987, 47, 1000–1003. [CrossRef]
88. Foresta, C.; Mioni, R.; Rossato, M.; Varotto, A.; Zorzi, M. Evidence for the Involvement of Sperm Angiotensin
Converting Enzyme in Fertilization. Int. J. Androl. 1991, 14, 333–339. [CrossRef]
89. Kohn, F.M.; Miska, W.; Schill, W.B. Release of Angiotensin-Converting Enzyme (ACE) from Human
Spermatozoa during Capacitation and Acrosome Reaction. J. Androl. 1995, 16, 259–265.
90. Shibahara, H.; Kamata, M.; Hu, J.; Nakagawa, H.; Obara, H.; Kondoh, N.; Shima, H.; Sato, I. Activity of Testis
Angiotensin Converting Enzyme (ACE) in Ejaculated Human Spermatozoa. Int. J. Androl. 2001, 24, 295–299.
[CrossRef]
91. Siems, W.E.; Heder, G.; Hilse, H.; Baeger, I.; Engel, S.; Jentzsch, K.D. Angiotensin-Converting Enzyme and
Other Peptidolytic Enzymes in Human Semen and Relations to its Spermatologic Parameters. Andrologia
1991, 23, 185–189. [CrossRef]
92. Yamaguchi, R.; Yamagata, K.; Ikawa, M.; Moss, S.B.; Okabe, M. Aberrant Distribution of ADAM3 in Sperm
from both Angiotensin-Converting Enzyme (Ace)—and Calmegin (Clgn)-Deficient Mice. Biol. Reprod. 2006,
75, 760–766. [CrossRef]
93. Gianzo, M.; Urizar-Arenaza, I.; Munoa-Hoyos, I.; Larreategui, Z.; Garrido, N.; Casis, L.; Irazusta, J.;
Subiran, N. Human Sperm Testicular Angiotensin-Converting Enzyme Helps Determine Human Embryo
Quality. Asian J. Androl. 2018, 20, 498–504. [PubMed]
94. Krege, J.H.; John, S.W.; Langenbach, L.L.; Hodgin, J.B.; Hagaman, J.R.; Bachman, E.S.; Jennette, J.C.;
O’Brien, D.A.; Smithies, O. Male-Female Differences in Fertility and Blood Pressure in ACE-Deficient Mice.
Nature 1995, 375, 146–148. [CrossRef] [PubMed]
95. Hagaman, J.R.; Moyer, J.S.; Bachman, E.S.; Sibony, M.; Magyar, P.L.; Welch, J.E.; Smithies, O.; Krege, J.H.;
O’Brien, D.A. Angiotensin-Converting Enzyme and Male Fertility. Proc. Natl. Acad. Sci. USA 1998, 95,
2552–2557. [CrossRef] [PubMed]
96. Inoue, N.; Kasahara, T.; Ikawa, M.; Okabe, M. Identification and Disruption of Sperm-Specific Angiotensin
Converting Enzyme-3 (ACE3) in Mouse. PLoS ONE 2010, 5, e10301. [CrossRef]
97. Vinson, G.P.; Mehta, J.; Evans, S.; Matthews, S.; Puddefoot, J.R.; Saridogan, E.; Holt, W.V.; Djahanbakhch, O.
Angiotensin II Stimulates Sperm Motility. Regul. Pept. 1996, 67, 131–135. [CrossRef]
98. Wennemuth, G.; Babcock, D.F.; Hille, B. Distribution and Function of Angiotensin II Receptors in Mouse
Spermatozoa. Andrologia 1999, 31, 323–325.
99. Sabeur, K.; Vo, A.T.; Ball, B.A. Effects of Angiotensin II on the Acrosome Reaction in Equine Spermatozoa.
J. Reprod. Fertil. 2000, 120, 135–142. [CrossRef]
100. Vinson, G.P.; Puddefoot, J.R.; Ho, M.M.; Barker, S.; Mehta, J.; Saridogan, E.; Djahanbakhch, O. Type 1
Angiotensin II Receptors in Rat and Human Sperm. J. Endocrinol. 1995, 144, 369–378. [CrossRef]
101. Gur, Y.; Breitbart, H.; Lax, Y.; Rubinstein, S.; Zamir, N. Angiotensin II Induces Acrosomal Exocytosis in
Bovine Spermatozoa. Am. J. Physiol. 1998, 275, E87–E93. [CrossRef]
102. Valdivia, A.; Cortés, L.; Beitia, M.; Totorikaguena, L.; Agirregoitia, N.; Corcostegui, B.; Casis, L.; Matorras, R.;
Irazusta, J.; Agirregoitia, E. Role of Angiotensin-(1–7) Via MAS Receptor in Human Sperm Motility and
Acrosome Reaction. Reproduction 2020, 159, 241–249. [CrossRef]
103. Subiran, N.; Agirregoitia, E.; Valdivia, A.; Ochoa, C.; Casis, L.; Irazusta, J. Expression of Enkephalin-Degrading
Enzymes in Human Semen and Implications for Sperm Motility. Fertil. Steril. 2008, 89, 1571–1577. [CrossRef]
104. Togo, T.; Morisawa, M. Aminopeptidase-Like Protease Released from Oocytes Affects Oocyte Surfaces and
Suppresses the Acrosome Reaction in Establishment of Polyspermy Block in Oocytes of the Mussel Mytilus
Edulis. Dev. Biol. 1997, 182, 219–227. [CrossRef] [PubMed]
105. Togo, T.; Morisawa, M. GPI-Anchored Aminopeptidase is Involved in the Acrosome Reaction in Sperm of
the Mussel Mytilusedulis. Mol. Reprod. Dev. 2004, 67, 465–471. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 7943 18 of 18
106. Khatun, A.; Rahman, M.S.; Ryu, D.Y.; Kwon, W.S.; Pang, M.G. Elevated Aminopeptidase N Affects Sperm
Motility and Early Embryo Development. PLoS ONE 2017, 12, e0184294. [CrossRef] [PubMed]
107. Khatun, A.; Kang, K.H.; Ryu, D.Y.; Rahman, M.S.; Kwon, W.S.; Pang, M.G. Effect of Aminopeptidase N
on Functions and Fertility of Mouse Spermatozoa in Vitro. Theriogenology 2018, 118, 182–189. [CrossRef]
[PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
